Advertisement

HSS Journal

, Volume 5, Issue 2, pp 169–177 | Cite as

Overlap Between Systemic Lupus Erythematosus and Kikuchi Fujimoto Disease

A Clinical Pathology Conference held by the Department of Rheumatology at Hospital for Special Surgery
  • Jessica K. GordonEmail author
  • Cynthia Magro
  • Theresa Lu
  • Robert Schneider
  • April Chiu
  • Richard R. Furman
  • Garron Solomon
  • Anne Bass
  • Doruk Erkan
Clinical Pathology Conference

CPC: overlap between systemic lupus erythematosus and kikuchi fujimoto disease

Case presentation

A 33-year-old African-Caribbean man with a history of possible Kikuchi Fujimoto disease (KFD) versus systemic lupus erythematosus (SLE) was evaluated for 3 weeks of fevers to 38.9°C and cough accompanied by fatigue, anorexia, weight loss, diffuse rash, lymphadenopathy, and oral and nasal ulcers.

His past medical history was significant for a hospitalization for febrile neutropenia 2 years prior to this evaluation. At that time, he presented with 2 weeks of fever, shaking chills, malaise, arthralgia, and myalgia. This had been preceded by 2 months of fatigue, 10-lb weight loss, and the development of scarring alopecia. He was noted at this time to have had diffuse lymphadenopathy, including the occipital, anterior, and posterior cervical regions. He also was found to have malar erythema, oral ulcers, and a rash on his scalp, ears, face, chest, arms, and legs. The rash was characterized by...

Keywords

Systemic Lupus Erythematosus Systemic Lupus Erythematosus Patient Hydroxychloroquine Plasmacytoid Dendritic Cell Phenotypic Profile 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jang YJ, Park KH Seok HJ (2000) Management of Kikuchi’s disease using glucocorticoid. J. Laryngol. Otol. 114:709–11PubMedCrossRefGoogle Scholar
  2. 2.
    Rezai K, Kuchipudi S, Chundi V (2004) Kikuchi–Fujimoto disease: hydroxychloroquine as a treatment. Clin. Infect. Dis 39:e124–e126PubMedCrossRefGoogle Scholar
  3. 3.
    Lawrence RC, Helmick CG, Arnett FC (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41:778–799PubMedCrossRefGoogle Scholar
  4. 4.
    Jimenez S, Cervera R, Font J (2003) The epidemiology of systemic lupus erythematosus. Clin. Rev. Allergy Immunol. 25:3–12PubMedCrossRefGoogle Scholar
  5. 5.
    El-Ramahi KM, Karrar A, Ali MA (1994) Kikuchi disease and its association with systemic lupus erythematosus. Lupus 3:409–11PubMedCrossRefGoogle Scholar
  6. 6.
    Goldblatt F, Andrews J, Russell A, Isenberg D (2008) Association of Kikuchi–Fujimoto’s disease with SLE. Rheumatology 47:554–555Google Scholar
  7. 7.
    Eisner MD, Amory J, Mullaney B (1996) Necrotizing lymphadenitis associated with systemic lupus erythematosus. Semin. Arthritis Rheum. 26:1–6CrossRefGoogle Scholar
  8. 8.
    Ohshima K, Karube K, Hamasaki M (2004) Apoptosis- and cell cycle-associated gene expression profiling of histiocytic necrotising lymphadenitis. Eur. J. Haematol. 72:322–9PubMedCrossRefGoogle Scholar
  9. 9.
    Kato K, Ohshima K, Anzai K (2001) Elevated serum-soluble Fas ligand in histiocytic necrotizing lymphadenitis. Int. J. Hematol. 73:84–6PubMedCrossRefGoogle Scholar
  10. 10.
    Kozyrev SV, Lewén S, Reddy PM (2007) Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 56:1234–41PubMedCrossRefGoogle Scholar
  11. 11.
    Niewold TB, Kelly JA, Flesch MH (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 58:2481–7PubMedCrossRefGoogle Scholar
  12. 12.
    Graham RR, Kyogoku C, Sigurdsson S, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 104:6758–6763Google Scholar
  13. 13.
    Kirou KA, Mavragani CP, Crow MK (2007) Activation of typeI interferon in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 3:579–588Google Scholar
  14. 14.
    Barrat FJ, Meeker T, Gregorio J, et al. (2005) Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202:1131–1139Google Scholar
  15. 15.
    Cella M, Jarrossay D, Facchetti F (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919–923PubMedCrossRefGoogle Scholar
  16. 16.
    Qu C, Moran TM, Randolph GJ (2003) Autocrine type I IFN and contact with endothelium promote the presentation of influenza A virus by monocyte-derived APC. J. Immunol 170:1010–1018PubMedGoogle Scholar
  17. 17.
    Tsang WY, Chan JK, Ng CS (1994) Kikuchi’s lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual features. Am. J. Surg. Pathol. 18:219–231PubMedCrossRefGoogle Scholar
  18. 18.
    Heremans H, Billiau A, Colombatti A (1978) Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect. Immun. 21:925–930PubMedGoogle Scholar
  19. 19.
    Braun D, Geraldes P, Demengeot J (2003) Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J. Autoimmun. 20:15–25PubMedCrossRefGoogle Scholar
  20. 20.
    Adam C, Thoua Y, Ronco P (1980) The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin. Exp. Immunol. 40:373–382PubMedGoogle Scholar
  21. 21.
    Mathian A, Weinberg A, Gallegos M (2005) IFN-{alpha} induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but Not in BALB/c Mice. J. Immunol. 174:2499–2506PubMedGoogle Scholar
  22. 22.
    Santiago-Raber ML, Baccala R, Haraldsson KM (2003) Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice. J. Exp. Med. 197:777–788PubMedCrossRefGoogle Scholar
  23. 23.
    Hron JD, Peng SL (2004) Type I IFN protects against murine lupus. J. Immunol. 173:2134–2142PubMedGoogle Scholar
  24. 24.
    Baechler EC, Batliwalla FM, Karypis G (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100:2610–2615PubMedCrossRefGoogle Scholar
  25. 25.
    Crow MK, Kirou KA, Wohlgemuth J (2003) Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 36:481–490PubMedCrossRefGoogle Scholar
  26. 26.
    Bennett L, Palucka AK, Arce E (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197:711–723PubMedCrossRefGoogle Scholar
  27. 27.
    Kirou KA, Lee C, George S (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 50:3958–3967PubMedCrossRefGoogle Scholar
  28. 28.
    Farkas L, Beiske K, Lund-Johansen F (2001) Plasmacytoid dendritic cells (natural interferon- {{alpha}}/{beta}-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159:237–243PubMedGoogle Scholar
  29. 29.
    Blomberg S, Eloranta ML, Cederblad B (2001) Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 10:484–490PubMedCrossRefGoogle Scholar
  30. 30.
    Nakano H, Yanagita M, Gunn MD (2001) CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171–1178PubMedCrossRefGoogle Scholar
  31. 31.
    Yoneyama H, Matsuno K, Toda E (2005) Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J. Exp. Med. 202:425–435PubMedCrossRefGoogle Scholar
  32. 32.
    Shiow LR, Rosen DB, Brdickova N, et al., CD69 acts downstream of interferon-[alpha]/[beta] to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440: 540–544.Google Scholar

Copyright information

© Hospital for Special Surgery 2009

Authors and Affiliations

  • Jessica K. Gordon
    • 1
    Email author
  • Cynthia Magro
    • 2
  • Theresa Lu
    • 1
  • Robert Schneider
    • 3
  • April Chiu
    • 4
  • Richard R. Furman
    • 5
  • Garron Solomon
    • 2
  • Anne Bass
    • 1
  • Doruk Erkan
    • 1
  1. 1.Department of RheumatologyHospital for Special SurgeryNew YorkUSA
  2. 2.Department of DermatopathologyWeill-Cornell Medical College-New York Presbyterian HospitalNew YorkUSA
  3. 3.Department of RadiologyHospital for Special SurgeryNew YorkUSA
  4. 4.Department of PathologyWeill-Cornell Medical College-New York Presbyterian HospitalNew YorkUSA
  5. 5.Division of Hematology and OncologyWeill-Cornell Medical College–New York Presbyterian HospitalNew YorkUSA

Personalised recommendations